Huanqing Li

Huanqing Li


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in Regenerative Therapy
Verified
Journal Article
Open access
HLHuanqing Li
Huanqing Li
SXShuai Xue
Shuai Xue
XZXiaohong Zhang
Xiaohong Zhang
FLFan Li
Fan Li
SBSonghua Bei
Songhua Bei
LFLi Feng
Li Feng
Gastric cancer (GC) progression is related with gene regulations. This study explored underlying regulatory axis of circRNA PVT1 (circPVT1) in GC. GC cell lines were detected for circPVT1 expression with the normal mucous epithelial cell GES-1 as control. After regulation of circPVT1, miR-423-5p and SMAD3 expression through transfection, CCK8 evaluated the cell viability, Transwell measured the migratory and invasive capability of cells. Luciferase verified the paired bindings between miR-423-5p and CircPVT1 or SMAD3. The functions of CircPVT1/miR-423-5p/SMAD3 were evaluated using RT-PCR, CCK8, Transwell assays. Western blot analyzed EMT-related proteins and phosphorylation of Smad3 in GC cells. Immunofluorescence method was used to evaluate the EMT-related proteins as well. CircPVT1 displayed higher expression in GC cells and knockdown led to decrease in cell growth, invasion and migration. CircPVT1 was targeted by miR-423-5p as a ceRNA of SMAD3. miR-423-5p upregulation suppressed both cicRNA PVT1 and SMAD3 in GC cells. Decrease in SMAD3 expression suppressed CircPVT1 by releasing miR-423-5p in cells, inhibiting cell growth, invasion and migration and suppressing the EMT process. CircPVT1 modulated cell growth, invasion and migration through EMT mediation in gastric cancer through miR-423-5p/Smad3 pathway.

22 May 2025 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
JWJiayi Wang
Jiayi Wang
DLDeming Li
Deming Li
FYFangzhou Ye
Fangzhou Ye
JLJian Li
Jian Li
ZQZhe Qing
Zhe Qing
LFLi Feng
Li Feng
Background and Aim: The researches on the global burden of digestive system malignancy in young populations were limited. This study aimed to comprehensively investigate the burden of early‐onset digestive system malignancy (often defined as cancers diagnosed below the age of 50) based on the Global Burden of Disease 2021.Methods: Data of incidence, prevalence, deaths, disability‐adjusted life years (DALYs), and risk factors for the five major early‐onset digestive system malignancies, including early‐onset esophageal cancer (EOEC), early‐onset gastric cancer (EOGC), early‐onset liver cancer (EOLC), early‐onset pancreatic cancer (EOPC), and early‐onset colorectal cancer (EOCRC), were extracted from GBD 2021. The average annual percent change (AAPC) was calculated using joinpoint regression analysis. The Bayesian age–period–cohort (BAPC) model was utilized to predict the burden up to 2030.Results: From 1990 to 2021, the age‐standardized incidence rate (ASIR) of early‐onset digestive system malignancies, except for EOCRC (AAPC, 0.37), showed a decreasing pattern. Meanwhile, the age‐standardized mortality rate (ASMR) and age‐standardized DALYs rate (ASDR) of early‐onset digestive system malignancy presented a downward trend. Notably, high‐middle sociodemographic index (SDI) countries experienced higher disease burdens. Dietary risk factors, tobacco, alcohol consumption, and metabolic factors were the main risk factors. The ASIR of EOEC and EOCRC was projected to increase in 2030, whereas the trend for EOGC, EOLC, and EOPC was projected to decrease.Conclusions: Early‐onset digestive system malignancy presented notable heterogeneity across gender, geography, and cancer types. This emphasizes the urgency of addressing the public health challenge of early‐onset digestive system malignancy.

20 November 2024 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
JJJun Jiang
Jun Jiang
DLDeming Li
Deming Li
FLFan Li
Fan Li
HLHuanqing Li
Huanqing Li
XZXiaohong Zhang
Xiaohong Zhang
LFLi Feng
Li Feng

16 March 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
FYFangzhou Ye
Fangzhou Ye
JLJian Li
Jian Li
JWJiayi Wang
Jiayi Wang
JFJiajun Fan
Jiajun Fan
XSXia Sheng
Xia Sheng
LFLi Feng
Li Feng
Tumor CMTM6 is known to regulate programmed death-ligand 1 expression and affect the cytotoxicity of infiltrating T cells, while its impact on natural kill

17 March 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
JJJun Jiang
Jun Jiang
XZXiaohong Zhang
Xiaohong Zhang
FYFangzhou Ye
Fangzhou Ye
PQPeiyu Qian
Peiyu Qian
FLFan Li
Fan Li
LFLi Feng
Li Feng
Background While growing evidence highlights the significance of metabolic reprogramming in colorectal cancer (CRC), the exact mechanisms behind these changes remain unclear. This study sought to identify key metabolic regulators and clarify their downstream pathways in CRC progression. Methods Three independent CRC datasets were subjected to differential expression analysis and lactylation-related gene screening, resulting in candidate genes, among which the STC2 gene was prioritized. STC2 expression was first assessed in HIEC-6, Caco-2, LoVo, SW480, and HCT116 cells. STC2 knockdown and overexpression models were established in HCT116 cells to examine their effects on proliferation, migration, invasion, and apoptosis. Lactate production and glucose uptake tests, Western blot, chromatin immunoprecipitation (ChIP), and Quantitative real-time polymerase chain reaction (qRT-PCR) were utilized to delineate the molecular mechanisms. A xenograft mouse model was applied to validate in vivo effects. Results STC2 levels in CRC cells are significantly higher than in normal intestinal cells. STC2 knockdown inhibits cell growth and glycolysis, but its overexpression significantly enhances these activities. Mechanistically, STC2 enhanced c-Myc activity through the PI3K/AKT/mTOR pathway, which upregulated GLUT1 and LDHA to maintain glycolytic flux. ChIP analysis showed that c-Myc occupancy on the GLUT1 and LDHA promoters was increased under STC2 overexpression, whereas binding was reduced upon STC2 silencing. In vivo, STC2 overexpression accelerated tumor growth and enhanced glycolysis in a xenograft mouse model. Conclusion These findings highlight STC2 as a key regulator of CRC progression, which regulates c-Myc-driven glycolysis through the PI3K/AKT/mTOR pathway. Targeting STC2 or its downstream metabolic effectors may provide new therapeutic strategies for CRC management.